Correlation Between Xilio Development and Mineralys Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Xilio Development and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Xilio Development and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Xilio Development and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Xilio Development and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Xilio Development with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Xilio Development and Mineralys Therapeutics,.

Diversification Opportunities for Xilio Development and Mineralys Therapeutics,

-0.25

Correlation Coefficient

Xilio Development  Mineralys Therapeutics,

Very good diversification

The 3 months correlation between Xilio and Mineralys is -0.25. Overlapping area represents the amount of risk that can be diversified away by holding Xilio Development and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Xilio Development is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Xilio Development are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Xilio Development i.e., Xilio Development and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between Xilio Development and Mineralys Therapeutics,

Considering the 90-day investment horizon Xilio Development is expected to generate 2.35 times more return on investment than Mineralys Therapeutics,. However, Xilio Development is 2.35 times more volatile than Mineralys Therapeutics, Common. It trades about 0.03 of its potential returns per unit of risk. Mineralys Therapeutics, Common is currently generating about 0.07 per unit of risk. If you would invest  97.00  in Xilio Development on December 29, 2024 and sell it today you would lose (22.00) from holding Xilio Development or give up 22.68% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Xilio Development  vs.  Mineralys Therapeutics, Common

Xilio Development

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Xilio Development are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Xilio Development displayed solid returns over the last few months and may actually be approaching a breakup point.

Mineralys Therapeutics,

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Mineralys Therapeutics, unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Xilio Development and Mineralys Therapeutics,

The main advantage of trading using opposite Xilio Development and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Xilio Development position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.

The idea behind Xilio Development and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.